Browsing Tag
Johnson & Johnson
102 posts
Johnson & Johnson seeks EMA approval to expand AKEEGA use for HRR-altered prostate cancer patients
Johnson & Johnson files for EMA approval to extend AKEEGA use in high-risk prostate cancer. Find out how this combo may redefine standard of care.
Why are Johnson & Johnson’s ACUVUE OASYS MAX 1‑Day lenses gaining attention from investors and eye care professionals?
Will Johnson & Johnson’s new dual-correction lens reshape the global eye care market? Discover what’s next in the presbyopia and astigmatism segment.
Johnson & Johnson launches world’s first daily disposable lens for astigmatism and presbyopia
Johnson & Johnson unveils world’s first daily disposable lens for astigmatism and presbyopia. Discover how this innovation could shift global eye care.
Johnson & Johnson posts sustained superiority for IMAAVY in gMG vs rival FcRn blockers in 24-week indirect comparison
New 24-week comparison shows Johnson & Johnson’s IMAAVY outperforms other FcRn blockers in gMG control—see what this means for patients and investors.
How Protagonist Therapeutics is building a multi‑indication macrocyclic peptide portfolio with icotrokinra and beyond
Protagonist Therapeutics is building a multi-indication oral biologics platform with icotrokinra and rusfertide. Learn how its macrocyclic peptides are redefining therapy.
Johnson & Johnson’s DARZALEX FASPRO shows 95% survival at 4 years in multiple myeloma
DARZALEX FASPRO shows 95% four-year PFS and deep MRD responses in NDMM, raising its profile as a foundational frontline therapy. Read the full trial analysis.
Leyden Labs secures €20m from European Investment Bank: Could this reshape Europe’s pandemic response strategy?
Leyden Labs secures €20M EIB funding under HERA Invest to develop intranasal antibody sprays targeting pandemic flu and respiratory threats.
Halozyme Therapeutics stock rises 6.27% after beating Q1 expectations, raising 2025 outlook
Halozyme Therapeutics stock rose as Q1 earnings beat expectations and 2025 guidance improved. See how ENHANZE® drives royalty growth and future prospects.
China just blinked: U.S. drugs spared from tariff hike—Here’s what that means
China exempts select U.S. pharmaceuticals from new 125% tariffs; firms like CSL and Merck assess supply chain resilience.
Johnson & Johnson’s TAR-200 delivers over 80% disease-free survival, offering new hope in BCG-unresponsive high-risk papillary NMIBC
Discover how Johnson & Johnson’s TAR-200 is redefining bladder cancer treatment with over 80% disease-free survival and 94% bladder preservation today!